Showing results (21-30 of 221) with videos related to

Sort By:
Pageof 23
Molecular Cancer Therapeutics|September 18, 2020
Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian CancerMark Seungwook Kim, Shaolin Ma, Anca Chelariu-Raicu, et al.
The Journal of Sexual Medicine|April 4, 2022
The Impact of the COVID-19 Pandemic on Sexual Health in Cis Women Living in GermanyFalk Batz, Eva Lermer, Laura Hatzler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2012
The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancerBrian M Slomovitz, Robert L Coleman
International Journal of Molecular Sciences|August 27, 2021
Trace Amine-Associated Receptor 1 (TAAR1) Is a Positive Prognosticator for Epithelial Ovarian CancerTilman L R Vogelsang, Aurelia Vattai, Elisa Schmoeckel, et al.
International Journal of Molecular Sciences|September 10, 2021
Prostaglandin E2 Receptor 4 (EP4) Affects Trophoblast Functions via Activating the cAMP-PKA-pCREB Signaling Pathway at the Maternal-Fetal Interface in Unexplained Recurrent MiscarriageLin Peng, Anca Chelariu-Raicu, Yao Ye, et al.
Current Oncology Reports|October 22, 2008
Uterine sarcoma 2008Jeff F Lin, Brian M Slomovitz
Gynecologic Oncology|November 27, 2020
A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancerAnca Chelariu-Raicu, Alpa Nick, Renata Urban, et al.
Breast (Edinburgh, Scotland)|November 4, 2021
COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspectiveMarie Forster, Rachel Wuerstlein, Alexander Koenig, et al.
International Journal of Molecular Sciences|December 4, 2020
Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression ProfileMingjun Zheng, Heather Mullikin, Anna Hester, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 21, 2022
A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovaryAnca Chelariu-Raicu, Eva Holley, Doris Mayr, et al.
Pageof 23